Huntington's Disease Market Poised for 14% CAGR Growth Through 2036 as Disease-Modifying Therapies Advance
Key Insights
The Huntington's disease (search) treatment market across the 7MM was valued at approximately USD 320 million in 2025 and is projected to grow at a 14% CAGR from 2026 to 2036.
Skyhawk Therapeutics (search)' SKY-0515 demonstrated a 62% dose-dependent reduction in mutant huntingtin (search) protein at the 9 mg dose in a nine-month interim analysis, with Phase II/III FALCON-HD now enrolling globally.
UniQure's AMT-130 gene therapy met its Phase I/II primary endpoint, significantly slowing symptom progression, and the company plans to file an MAA with the UK MHRA in Q3 2026.
The global Huntington's disease (search) therapeutics market is entering a transformative era, with the total market size across the seven major markets (7MM) reaching approximately USD 320 million in 2025 and projected to expand at a compound annual growth rate (CAGR) of 14% during the 2026–2036 forecast period, according to a comprehensive report from DelveInsight (search). This growth is being fueled by progress in precision medicine, rising R&D investments, and the anticipated commercialization of disease-modifying therapies that target the underlying genetic drivers of the disease rather than merely managing symptoms.
The United States accounted for the largest share of the Huntington's disease (search) treatment market in 2025, with AUSTEDO (deutetrabenazine) capturing the highest revenue among available therapies at USD 167 million. In the U.S. alone, the total number of prevalent cases stood at 44,000 in 2025, a figure expected to rise over the forecast period. Across the EU4 countries, the UK, and Japan, an additional 37,000 prevalent cases were recorded, with Huntington's disease disproportionately affecting individuals aged 60 and older, who represent approximately 50% of total cases in the 7MM.
A Pipeline Shifting from Symptom Management to Disease Modification
Current treatment options—including AUSTEDO, INGREZZA (valbenazine), and generic tetrabenazine formulations—are largely directed toward symptomatic relief, particularly the management of chorea, and do not alter the underlying disease course. This reality underscores a considerable unmet need that the emerging pipeline is poised to address.
"The therapeutic pipeline is advancing rapidly, with gene therapies, antisense oligonucleotides, and RNA-targeted modalities being developed to address the root cause of the disease and potentially slow its progression rather than solely alleviate symptoms," the DelveInsight (search) report notes. Sharad Chandra Vinayak, Assistant Project Manager of Forecasting at DelveInsight, added that "increasing research investments, patient advocacy, and clinical trial activity are accelerating innovation, while improved disease awareness is expected to support market expansion over the forecast period."
SKY-0515: Oral Small-Molecule RNA Modulator Shows Early Promise
Skyhawk Therapeutics (search)' SKY-0515, an investigational oral small-molecule RNA modulator developed using the company's proprietary SKYSTAR RNA-targeting platform, has emerged as one of the most closely watched candidates. The therapy is designed to lower levels of both huntingtin (HTT (search)) and PMS1 (search) proteins—the latter being a recognized contributor to somatic CAG repeat expansion and Huntington's disease (search) progression.
In January 2026, Skyhawk reported encouraging results from a nine-month interim analysis of its Phase I trial. SKY-0515 achieved dose-dependent reductions in mutant huntingtin (search) (mHTT) protein, reaching 62% at the 9 mg dose, along with a 26% dose-dependent decrease in PMS1 (search) mRNA. The therapy also demonstrated strong central nervous system exposure and was generally safe and well tolerated. In a Phase I study involving healthy volunteers, SKY-0515 showed a dose-dependent reduction in HTT (search) mRNA, achieving an average 72% decrease at the highest dose.
By June 2025, Skyhawk had dosed the first patient in its Phase II/III FALCON-HD trial, which has since expanded from its initial twelve sites in Australia and New Zealand to a broader global footprint, with more than 90 patients treated to date. In March 2026, the Australian Therapeutic Goods Administration (TGA) determined that SKY-0515 qualifies for registration through the provisional approval pathway.
AMT-130: Gene Therapy Charts a Path Toward Regulatory Filing
UniQure Biopharma (search)'s AMT-130, a gene therapy candidate based on an AAV5 vector engineered to deliver an artificial microRNA that suppresses expression of the huntingtin gene via the company's proprietary miQURE technology, represents a potentially transformative approach. By reducing production of mutant huntingtin (search) protein, AMT-130 aims to address the underlying cause of Huntington's disease (search).
In September 2025, UniQure reported positive top-line results from its Phase I/II study, with AMT-130 significantly slowing symptom progression and meeting the trial's primary endpoint—marking the first time a therapy has demonstrated the ability to alter the course of Huntington's disease (search) in a clinical setting. However, the regulatory path has been uneven. In November 2025, the U.S. FDA questioned the sufficiency of the Phase I/II trial data, indicating it would not be adequate for a biologics license application—a "drastic change" from prior guidance, according to UniQure. In March 2026, the FDA reiterated that current data are not sufficient to support approval.
Despite this setback in the U.S., UniQure completed a Pre-Submission Meeting with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2026 and intends to file a Marketing Authorization Application for AMT-130 in the third quarter of 2026.
Additional Pipeline Candidates Advance
PTC Therapeutics, in collaboration with Novartis, is developing PTC518 (votoplam), a novel small-molecule splicing modifier that reduces huntingtin protein production by promoting inclusion of a pseudoexon containing a premature stop codon within HTT (search) mRNA, leading to mRNA degradation. In April 2026, PTC Therapeutics announced positive topline findings from the 24-month interim analysis of the PIVOT-HD long-term extension study, demonstrating favorable dose-dependent impacts on disease progression in Stage 2 Huntington's disease (search) patients treated with votoplam for 24 months compared with an external natural history cohort.
Prilenia Therapeutics (search)' pridopidine, a first-in-class, highly selective Sigma-1 receptor agonist with demonstrated neuroprotective potential, has received Orphan Drug Designation for Huntington's disease (search) in both the United States and Europe, as well as Fast Track Designation from the U.S. FDA.
Other notable candidates in the pipeline include bevantolol (SOM3355) from SOM Innovation Biotech, RG6042 (tominersen) from Novartis, WVE-003 from Wave Life Sciences, ALN-HTT02 from Alnylam Pharmaceuticals, VO659 from Vico Therapeutics, and ANX-005 from Annexon.
Market Dynamics and Outlook
Key obstacles within the treatment landscape include the absence of approved disease-modifying therapies, heterogeneity in disease progression among patients, modest effectiveness of symptomatic treatments, and concerns regarding long-term safety and tolerability of existing options. Nevertheless, the anticipated launch of emerging therapies is poised to transform the Huntington's disease (search) market landscape. As these cutting-edge therapies mature and gain regulatory approval, they are expected to reshape standards of care and unlock opportunities for medical innovation and economic growth across the 7MM.